BPC-157 Dosage & Research Protocols: Complete Scientific Guide

What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is derived from a sequence found within the gastric mucosal protective protein BPC, isolated from human gastric juice by researcher Predrag Sikiric and colleagues at the University of Zagreb School of Medicine beginning in the late 1980s.

The peptide is distinct from its parent protein in that it was designed as a stable, synthetic fragment that retains and amplifies the tissue-protective properties of the endogenous BPC protein while being resistant to acid degradation — a feature that made it attractive for both parenteral and intragastric research models.

As of 2026, BPC-157 has been the subject of more than 150 peer-reviewed publications, primarily from preclinical animal studies. No phase III clinical trials have been completed. All Rainbow Peptide BPC-157 is supplied exclusively for in vitro and animal research by qualified investigators.

Research History & Origin

The isolation of BPC from human gastric juice was first reported by Sikiric et al. in 1993, with the specific pentadecapeptide fragment BPC-157 characterised and given its numerical designation in the same period. Early research centered on gastrointestinal protective effects — specifically the ability of the compound to accelerate healing in rodent models of gastric ulcer, oesophageal lesion, and intestinal fistula.

By the early 2000s, the Zagreb group had expanded research into musculoskeletal applications, publishing a series of studies on tendon-to-bone healing, ligament repair, and muscle crush injury models. A landmark 2003 paper demonstrated accelerated Achilles tendon healing in rat models, which drew significant attention from sports science and orthopedic research communities.

The compound has also been studied in central nervous system models (dopamine system modulation, spinal cord injury), inflammatory bowel disease models, and most recently in cardiovascular and wound healing applications. Researcher interest has grown substantially from 2020–2026, coinciding with broader public awareness of peptide research.

Preclinical Dose Parameters

The following dosing parameters are extracted from published peer-reviewed literature and represent ranges used in preclinical animal research only. They are provided for scientific reference and cannot be extrapolated to human use under any circumstances.

Rodent Studies (Rat Models — Most Common)

The majority of BPC-157 literature uses Sprague-Dawley or Wistar rats (typically 200–350 g body weight). Published doses range from:

• Low dose: 1 µg/kg body weight (~0.2–0.35 µg per rat)
• Standard dose: 10 µg/kg body weight (~2–3.5 µg per rat)
• High dose: 100 µg/kg body weight (used in some models; effects often equivalent to 10 µg/kg)

Notably, several published studies report a dose-independent or "ceiling effect" phenomenon — with 1 µg/kg and 10 µg/kg producing similar biological endpoints, suggesting receptor saturation or indirect signalling mechanisms rather than simple dose-response kinetics.

Dosing Frequency in Published Protocols

Administration schedules in published studies vary by model:

• Acute injury models: Single dose at time of injury, or daily for 7–14 days
• Chronic IBD models: Daily administration for 4–8 weeks
• Tendon/ligament healing: Daily for 14–28 days post-surgery
• CNS models: Daily for variable periods (5–21 days depending on model)

Stability in Diluted Solution

Research groups typically reconstitute lyophilized BPC-157 in bacteriostatic water or sterile physiological saline. Published protocols consistently note that BPC-157 solutions should be stored at 4°C and used within 7–14 days of reconstitution for maximum peptide integrity.

Administration Routes in Research

A notable feature of BPC-157 research is the range of administration routes that have been studied, with comparable biological effects observed across multiple routes — an unusual finding for a peptide compound:

Subcutaneous Injection (SC)

The most commonly reported route in musculoskeletal and wound healing studies. Injections are typically administered distally from the injury site, suggesting systemic rather than local mechanisms.

Intraperitoneal Injection (IP)

Used extensively in gastrointestinal, CNS, and inflammatory models. Rapid systemic distribution. Most pharmacokinetic studies in rodents have used IP administration.

Intragastric (Oral Gavage)

BPC-157's resistance to acid degradation makes it unusual among peptides in its ability to produce measurable systemic effects after oral administration in animal models. Several IBD and GI protection studies have used intragastric gavage as the primary route.

Intravenous (IV)

Less commonly used; reserved for specific pharmacokinetic and acute cardiovascular studies. Rapid clearance kinetics documented.

Topical

Some wound healing and corneal injury studies have applied BPC-157 directly to tissue surfaces; effectiveness appears comparable to systemic routes in these localised injury models.

Tissue Injury Models Studied

BPC-157 is distinctive in the breadth of tissue types across which its effects have been studied. The following represents a summary of published model categories:

Musculoskeletal & Connective Tissue

• Achilles tendon transection and repair models
• Rotator cuff tear models
• Medial collateral ligament (MCL) transection
• Quadriceps muscle crush injury
• Bone fracture healing (tibial defect models)

Gastrointestinal

• Gastric ulcer induction (ethanol, indomethacin, cysteamine models)
• Intestinal anastomosis healing
• Crohn's disease models (TNBS-induced colitis)
• Oesophageal lesion and reflux models
• Intestinal fistula models

Neurological

• Spinal cord compression injury
• Peripheral nerve crush (sciatic nerve transection)
• Dopamine system dysregulation models (haloperidol-induced)
• Traumatic brain injury models

Wound Healing & Skin

• Full-thickness skin excision models
• Burn wound models
• Corneal alkali injury models

Mechanism of Action Research

The mechanism by which BPC-157 produces its studied effects across diverse tissue types is not fully characterized, but several pathways have been identified in preclinical research:

• Nitric oxide (NO) system modulation: BPC-157 has been shown to modulate NO production in endothelial cells, with both pro- and anti-angiogenic effects observed depending on tissue context and injury type.
• Growth factor upregulation: Studies have documented increased expression of VEGF (vascular endothelial growth factor), EGF receptor activity, and FAK-paxillin pathway activation — consistent with accelerated angiogenesis and wound healing.
• Tendon fibroblast activation: In vitro studies show BPC-157 accelerates tendon fibroblast migration and outgrowth in scratch assay models, with the FAK signalling pathway identified as a key mediator.
• Cytoprotective effects: Multiple studies demonstrate protection of GI mucosal cells from NSAID-induced damage, potentially through cyclooxygenase-independent prostaglandin pathways.
• Dopamine system interaction: CNS research suggests BPC-157 modulates dopamine receptor sensitivity and counteracts dopaminergic dysregulation in rodent models, though mechanisms remain under investigation.

Peptide Stability & Storage

BPC-157 is supplied by Rainbow Peptide as a lyophilized (freeze-dried) white powder with ≥98% purity confirmed by HPLC and mass spectrometry (CoA available on request). Recommended storage and handling for research use:

• Lyophilized (dry): Store at −20°C, protected from light and moisture. Stable for 24+ months when stored correctly.
• Reconstituted solution: Store at 4°C. Use within 14 days. Avoid repeated freeze-thaw cycles.
• Reconstitution vehicle: Bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline commonly used in published protocols.
• Concentration: Most published studies reconstitute to 1 mg/mL stock solution, then dilute to working concentrations in saline.

BPC-157's stability in acidic conditions is well-documented and is considered a key feature distinguishing it from most other research peptides, which are rapidly degraded in gastric-pH environments.

BPC-157 vs. TB-500 in Research

BPC-157 and TB-500 (Thymosin Beta-4 fragment) are often studied in parallel for musculoskeletal repair applications. Key differences in published research:

A BPC-157 + TB-500 combination product is also available from Rainbow Peptide for research applications where investigators wish to study synergistic effects in multi-pathway tissue repair models.